CSA Medical Completes Enrollment in SPRAY-CB Trial for RejuvenAir System in Chronic Bronchitis Treatment

Monday, July 08, 2024

CSA Medical Inc. has announced the completion of patient enrollment in its SPRAY-CB pivotal trial, achieving this milestone nearly two months ahead of schedule.

This clinical trial, involving 210 patients worldwide, is a double-blind, sham-controlled, prospective, randomized study focused on treating COPD with Chronic Bronchitis.

The RejuvenAir System, already approved with CE Mark and UKCA certifications outside the U.S., employs liquid nitrogen spray cryotherapy to deliver a precise thermal dose to targeted lung areas.

This outpatient procedure represents a significant advance beyond pharmaceutical treatments for COPD, targeting the underlying cause of Chronic Bronchitis by ablating damaged airway cells responsible for mucus overproduction and clearance issues.

CSA Medical aims to offer a pioneering therapy for millions of patients through this innovative medical device.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress